mk-0616
merck
['cardio']
 presents mk-0616 phase 2 trial data will inform further development of mk-0616, a pcsk9 inhibitor, as a potentially highly effective oral ldl-c-lowering medication for pts with #hypercholesterolemia #acc23 #wccardio 
Consultant Cardiologist - Editor in chief #JACCcasereports - Chair TF women in CV imaging #EACVI  - Tweets are my own opinion#